Jump to content
Sclero Forums

Search the Community

Showing results for tags 'ps and psa'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 14 results

  1. Negative regulation of dendritic cell (DC) activation in psoriasis mediated via CD100-Plexin-B2. Our results uncovered a negative regulatory mechanism for DCs activation in psoriasis, which was mediated via CD100-Plexin-B2 in a cell type- and receptor- specific manner. PubMed, J Pathol, 01/14/2020. (Also see Psoriasis and Psoriatic Arthritis and Dendritic Cells) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review. Clinicians are urged to evaluate patients with psoriasis for psychiatric risk factors regardless of their therapy. PubMed, Cutis, 2019 Dec;104(6):361-365. (Also see Depression, Suicide Prevention and Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis (Ps) and psoriatic arthritis (PsA). Besides well-known genetic susceptibility loci, epigenetic DNA modifications, which are associated with Ps development, have been characterized recently. PubMed, Ther Adv Musculoskelet Dis, 2019 Nov 6;11:1759720X19886505. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Evidence for a role of autoinflammation in early-phase psoriasis. IL-1β overexpression in combination with low expression of cytokines that are predominant in late-phase plaque psoriasis may support the role of autoinflammation in early-phase disease. PubMed, Clin Exp Immunol, 09/11/2019. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. Exogenous replacement of IL-36 antagonists may be a novel promising therapeutic target for PsA patients. PubMed, Rheumatology (Oxford), 09/03/2019. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Association Between Psoriasis with Arthritis (PsA) and Hearing Impairment (HI) in US Adults: Data from the National Health and Nutrition Examination Survey. PsA is independently associated with a significantly increased risk of HI, which partially mediates an association with worsened psychiatric outcomes. PubMed, J Rheumatol, 2019 Jun;46(6):587-594. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Identification of Novel Autoantibodies Associated with Psoriatic Arthritis. Our findings suggest that these autoantibodies may be useful biomarkers and indicative of therapeutic targets of psoriasis and psoriatic arthritis. PubMed, Arthritis Rheumatol, 01/07/2019. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Improved patient–reported outcomes (PROs) in patients with psoriatic arthritis (PsA) treated with abatacept: results from a phase 3 trial. Abatacept treatment improved PROs in patients with PsA versus placebo, with better results in elevated baseline C-reactive protein and tumour necrosis factor inhibitor– naïve subpopulations. BMC Journals, Arthritis Research & Therapy, 12/06/2018. (Also see Psoriasis and Psoriatic Arthritis and Biologic Agents) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. The Effect of Pregnancy on Disease Activity in Patients with Psoriatic Arthritis. Continuation of biologics therapy was associated with a low level of disease activity and a low probability of flare during pregnancy. PubMed, J Rheumatol, 2018 Dec;45(12):1651-1655. (Also see Psoriasis and Psoriatic Arthritis and Biologic Agents) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress. The cytochrome c release into the extracellular space and tryptase may have a role in skin and joint inflammation. PubMed, Front Immunol, 2018 Oct 30;9:2363. (Also see Psoriasis and Psoriatic Arthritis and Oxidative Stress) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta–analysis. These findings suggest that psoriasis is significantly associated with IBD and gastroenterology consultation may be indicated when patients with psoriasis present with bowel symptoms. PubMed, JAMA Dermatol, 10/24/2018. (Also see Psoriasis and Psoriatic Arthritis and Inflammatory Bowel Disease) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Increased Prevalence of Metabolic Syndrome (MetS) and Adipocytokine Levels in a Psoriatic Arthritis(PsA) Cohort. Clinicians caring for PsA patients ought to be aware of the increased risk of MetS in PsA patients, confirmed in different regions worldwide. PubMed, J Clin Rheumatol, 2018 Sep;24(6):302-307. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Risk of type 2 diabetes (T2D) and cardiovascular disease in an incident cohort of people with psoriatic arthritis (PsA): A population–based cohort study. The development of T2D in an incident population of PsA is significantly higher than in psoriasis alone, whereas the increased risk of cardiovascular disease in PsA and psoriasis is similar. Rheumatology, 09/06/2018. (Also see Psoriasis and Psoriatic Arthritis and Symptoms and Complications of Diabetes) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. In this Perspectives article, we address the similarities and differences between these two sets of recommendations and the implications for patient management. PubMed, Nat Rev Rheumatol, 2016 Dec;12(12):743-750. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...